<DOC>
	<DOCNO>NCT00000769</DOCNO>
	<brief_summary>To determine safety tolerance interleukin-4 ( IL-4 ) patient AIDS-related Kaposi 's sarcoma . To determine effect IL-4 tumor growth patient AIDS-related Kaposi 's sarcoma . IL-4 exhibit variety beneficial effect immune system potent inhibitor Kaposi 's sarcoma cell vitro .</brief_summary>
	<brief_title>A Phase I/II Study Recombinant Interleukin-4 AIDS Kaposi 's Sarcoma</brief_title>
	<detailed_description>IL-4 exhibit variety beneficial effect immune system potent inhibitor Kaposi 's sarcoma cell vitro . Patients stratify two group accord CD4 count ( le 100 cells/mm3 great equal 100 cells/mm3 ) enrol cohort four patient four dose level IL-4 per stratum . Within stratum , patient give dose level receive least 2 week study therapy two patient experience grade 3 4 drug-related toxicity , dose escalation subsequent patient may begin . The MTD define dose 50 percent patient develop grade 3 bad toxicity . Patients CD4 count le 500 cells/mm3 ( per 12/30/94 amendment ) must antiretroviral therapy study treatment . PER AMENDMENT 11/20/95 : Group I - enrollment close , objective define . Group II - patient must CD4 cell great equal 100/mm3 less 500/mm3 . PER AMENDMENT 11/20/95 : All patient receive antiretroviral therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Interleukin-4</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Antiretroviral therapy study treatment patient CD4 count &lt; 500 cells/mm3 ( per 12/30/94 amendment ) . Allowed : GCSF second occurrence grade 3 4 neutropenia ( per 12/30/94 amendment ) . Nonsteroidal antiinflammatory agent include acetaminophen drugrelated fever . Systemic steroids 1 week 30day period . PCP prophylaxis TMP/SMX , dapsone , inhaled pentamidine , patient history PCP CD4 count &lt; 250 cells/mm3 . Allowed patient CD4 count &lt; 100 cells/mm3 : Maintenance dos ganciclovir , pyrimethamine/sulfa TMP/SMX stable , wellcontrolled opportunistic infection . Nonmyelosuppressive treatment IND medication . Prior Medication : Required : PER AMENDMENT 11/20/95 : Stable dose antiretroviral therapy require least 21 day prior study entry patient . ( Changed Stable dose antiretroviral therapy least 21 day prior study entry patient CD4 count &lt; 500 cells/mm3 ( per 12/30/94 amendment ) . Patients must : AIDSrelated Kaposi 's sarcoma . PER AMENDMENT 11/20/95 : CD4 lymphocyte count &gt; = 100 &lt; 500 cells/mm3 . ( Changed HIV infection . ) PER AMENDMENT 11/20/95 : All Patients receive antiretroviral therapy . ( Changed Current antiretroviral therapy IF CD4 count &lt; 500 cells/mm3 ( per 12/30/94 amendment ) . ) No active opportunistic infection require induction therapy . Consent parent guardian le 18 year age . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Other active malignancy ( except basal cell carcinoma skin situ cervical cancer ) . Alteration mental status may prevent compliance . Cardiac functional capacity Class II worse OR regional wall abnormality abnormal ejection fraction twodimensional echocardiogram , perform . Concurrent Medication : Excluded : Chemotherapy , interferon , immune modulators Kaposi 's sarcoma . Myelosuppressive agent induction dose ganciclovir , Fansidar ( pyrimethamine/sulfadoxine ) , investigational drug ( exception nonmyelosuppressive treatment IND medication specific patient ) . GMCSF erythropoietin ( except second grade 3/4 neutropenia anemia ) . GCSF . Patients follow prior condition exclude : History myocardial infarction significant arrhythmia . History symptomatic hypoglycemia . Prior Medication : Excluded : Systemic therapy ( include chemotherapy , interferon , immune modulators ) Kaposi 's sarcoma within 4 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Interleukin-4</keyword>
</DOC>